399 filings
6-K
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
20-F
2023 FY
GLPG
Galapagos NV
Annual report (foreign)
28 Mar 24
4:02pm
6-K
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
xymhd0
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
5mcvzuz6ih7t
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
v746jzav p1n
4 Jan 24
Current report (foreign)
5:32pm
6-K
3i9pb5t
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
ao9gx87m4 7x9xl
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
4rg9rzlvtvr lkyzdc
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
l8pq6bz 4de1unovoa
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
h3awxtqxh5cd2ildh
12 Dec 23
Current report (foreign)
6:00am
S-8
85fvlv9 cv92h4w5
4 Dec 23
Registration of securities for employees
5:16pm
6-K
ba9e3kc
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
8kqt7i2
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
ntxmdyu35j
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
ssxqly1e0 0nluq
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
n53vr4h xdzlw52d22i
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
ghmzkc a5zm3
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm